Effective multiagent chemotherapy in children with advanced B‐cell lymphoma: who remains the high risk patient?
- 1 February 1987
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 65 (2) , 159-164
- https://doi.org/10.1111/j.1365-2141.1987.tb02258.x
Abstract
Summary. Between 1981 and 1985. 50 patients, mainly children and adolescents, with advanced B‐cell lymphoma were entered on a protocol comprising eight drugs: cyclo‐phosphamide. vincristine, prednisolone. high dose methotrexate. adriamycin. BCNU. cytosine arabinoside and thioguanine. Treatment to the central nervous system consisted of intrathecal methotrexate and cytosine‐arabinoside in association with high dose methotrexate without irradiation. Data was collected prospectively with regard to response rate, treatment related complications and survival. Histology was reviewed in all referred cases and in 21 there was supportive evidence from immunological and cytogenetic studies. The overall complete response rate was 86%: 31/36 stage III and 12/14 stage IV. There were four treatment related deaths. The overall disease‐free survival is 75% with a median follow up of 32 months. In the group of stage IV patients 5/7 with only marrow involvement, 2/4 with isolated CNS involvement and 1/3 with combined CNS and marrow infiltration survive. All the patients with CNS involvement at presentation underwent consolidation treatment with high dose chemotherapy and bone marrow transplant.These results demonstrate the very high curability of B‐cell lymphoma using intensive multiagent therapy even with advanced abdominal disease. Bone marrow infiltration does not appear to be an adverse prognostic factor in isolation from bulk disease or CNS involvement. There remain, however, two groups of patients in whom further intensification of therapy is indicated, namely, those with initial CNS involvement, especially in combination with marrow infiltration, and those with extensive multiorgan involvement at presentation who fail to achieve remission with initial therapy. For the other patients, the large majority, a reduction in the intensity and duration of therapy is currently under study.This publication has 19 references indexed in Scilit:
- Curability of Burkitt's lymphoma with high-dose cyclophosphamide-high-dose methotrexate therapy and intrathecal chemoprophylaxis.Journal of Clinical Oncology, 1985
- High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas.Journal of Clinical Oncology, 1984
- Central nervous system involvement in American Burkitt's lymphoma.Journal of Clinical Oncology, 1983
- Childhood Non-Hodgkin's LymphomaNew England Journal of Medicine, 1983
- Burkitt-type lymphoma in France among non-Hodgkin malignant lymphomas in Caucasian childrenBritish Journal of Cancer, 1982
- The long-term outlook for children treated for non-Hodgkin lymphomas. A report of the Children's Solid Tumour GroupBritish Journal of Cancer, 1981
- A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary resultsMedical and Pediatric Oncology, 1980
- Pharmacokinetics of high-dose methotrexate treatment in childrenEuropean Journal of Clinical Pharmacology, 1978
- Treatment Results of 54 American Patients with Burkitt's Lymphoma Are Similar to the African ExperienceNew England Journal of Medicine, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958